Last reviewed · How we verify
Eosinophils
Eosinophils is a Biologic drug developed by Lithuanian University of Health Sciences. It is currently in Phase 1 development.
Eosinophils are a type of white blood cell involved in combating multicellular parasites and certain infections, as well as controlling mechanisms associated with allergy and asthma. They are granulocytes that develop during hematopoiesis in the bone marrow and are targeted by small molecule antagonists, such as CHF-6532, which act on the Prostaglandin D2 receptor 2.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Eosinophils |
|---|---|
| Sponsor | Lithuanian University of Health Sciences |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Budesonide as a Treatment for Low-grade Duodenal Inflammation in Functional Dyspepsia (Phase 4)
- Real Life Experience Survey of Dupilumab in the Netherlands (N/A)
- Prevalence of Allergic Diseases and Atopy in Patients With Angiographically Confirmed Coronary Artery Disease (N/A)
- Effect of Benralizumab on Airway Remodeling in Asthma (N/A)
- The Study of Differences in Eosinophil Function and Subsets in Patients With Eosinophilic Pulmonary Diseases Based on Flow Cytometry Analysis (N/A)
- A Phase II, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulm (Phase 2)
- Exacerbations of Severe Asthma in Patients Treated With Mepolizumab: Assessment of Biomarkers and Identification of Biologic Clusters (N/A)
- Phenotyping Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA): Clinical and Translational Correlation to Point-Of-Care Biomarkers (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eosinophils CI brief — competitive landscape report
- Eosinophils updates RSS · CI watch RSS
- Lithuanian University of Health Sciences portfolio CI
Frequently asked questions about Eosinophils
What is Eosinophils?
Who makes Eosinophils?
What development phase is Eosinophils in?
Related
- Manufacturer: Lithuanian University of Health Sciences — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing